阿托伐他汀联合阿司匹林可有效预防2型糖尿病继发心血管疾病

发布时间：2018-03-05 14:11

本文选题：型糖尿病　切入点：心血管疾病　出处：《基因组学与应用生物学》2017年03期 　论文类型：期刊论文

【摘要】：为探讨阿托伐他汀联合阿司匹林对预防2型糖尿病继发心血管疾病的临床效果与用药价值,本研究选取我院90例糖尿病患者,随机分为观察组和对照组,两组均实施常规降糖治疗,观察组另外给予阿托伐他汀联合阿司匹林治疗。治疗8月后,分别观察两组血脂水平、炎症因子水平和血管内皮功能,并随访2年。经过临床分析,治疗后观察组总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白(LDL-C)、炎症因子水平、ET-1均低于对照组,高密度脂蛋白(HDL-C)、一氧化氮(NO)水平高于对照组,差异显著(~*p0.05)。组内比较,治疗前后观察组血脂水平、炎症因子水平、内皮素-1(ET-1)及NO水平差异显著,有统计学意义(~#p0.05),对照组差异无统计学意义(~▲p0.05)。数据表明,阿托伐他汀联合阿司匹林可有效预防2型糖尿病继发心血管疾病,值得临床重视。
[Abstract]:In order to investigate the clinical effect and medication value of Atto vastatin combined with aspirin in the prevention of cardiovascular disease secondary to type 2 diabetes mellitus, 90 patients with diabetes mellitus in our hospital were randomly divided into observation group and control group. Both groups were treated with conventional hypoglycemic therapy, and the observation group were treated with Atto vastatin combined with aspirin. After August, the blood lipid level, inflammatory factor level and vascular endothelial function were observed, and followed up for 2 years. After treatment, the levels of TC, TG, LDL-Cn, and ET-1 in the observation group were all lower than those in the control group, and the levels of HDL-CU and no in the high density lipoprotein group were higher than those in the control group, and the difference was significant (P 0.05). Before and after treatment, the levels of blood lipid, inflammatory factors, endothelin-1 ET-1) and no in the observation group were significantly different (P < 0.05), but there was no significant difference between the control group and the control group. Atto vastatin combined with aspirin can effectively prevent type 2 diabetes secondary cardiovascular disease, deserves clinical attention.
【作者单位】：江苏联合职业技术学院南通卫生分院;
【基金】：江苏联合职业技术学院南通卫生分院资助
【分类号】：R54;R587.1

【相似文献】